Young Jae Byun1,2, Dylan A Levy1,3, Shaun A Nguyen1, Emily Brennan4, Habib G Rizk1. 1. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina. 2. Department of Medicine, University of Central Florida College of Medicine, Orlando, Florida. 3. Department of Medicine, Quinnipiac University Frank H. Netter MD School of Medicine, North Haven, Connecticut. 4. Department of Research and Education Services, Medical University of South Carolina Library, Charleston, South Carolina, U.S.A.
Abstract
OBJECTIVE: To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM). METHODS: Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta-analysis was performed on pre- and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement. RESULTS: Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3 years with female-to-male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β-blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined. CONCLUSIONS: Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side-effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta-analyses and for more evidence-based treatment of vestibular migraines. Laryngoscope, 131:186-194, 2021.
OBJECTIVE: To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM). METHODS: Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta-analysis was performed on pre- and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement. RESULTS: Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3 years with female-to-male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β-blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined. CONCLUSIONS: Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side-effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta-analyses and for more evidence-based treatment of vestibular migraines. Laryngoscope, 131:186-194, 2021.
Authors: Thomas Lempert; Jes Olesen; Joseph Furman; John Waterston; Barry Seemungal; John Carey; Alexander Bisdorff; Maurizio Versino; Stefan Evers; Amir Kheradmand; David Newman-Toker Journal: J Vestib Res Date: 2022 Impact factor: 2.354
Authors: Sabina Alexandra Cojocariu; Alexandra Maștaleru; Radu Andy Sascău; Cristian Stătescu; Florin Mitu; Maria Magdalena Leon-Constantin Journal: Medicina (Kaunas) Date: 2021-02-09 Impact factor: 2.430
Authors: Monica P Mallampalli; Habib G Rizk; Amir Kheradmand; Shin C Beh; Mehdi Abouzari; Alaina M Bassett; James Buskirk; Claire E J Ceriani; Matthew G Crowson; Hamid Djalilian; Joel A Goebel; Jeffery J Kuhn; Anne E Luebke; Marco Mandalà; Magdalena Nowaczewska; Nicole Spare; Roberto Teggi; Maurizio Versino; Hsiangkuo Yuan; Ashley Zaleski-King; Michael Teixido; Frederick Godley Journal: Front Neurol Date: 2022-01-03 Impact factor: 4.003